U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07426419) titled 'An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)' on Feb. 03.
Brief Summary: This is a Phase 1/2, open-label, dose-exploration and dose-expansion, clinical trial evaluating the safety, tolerability, pharmacodynamics, and preliminary efficacy of a single intravenous infusion of AFTX-201 in adults with dilated cardiomyopathy caused by a BAG3 gene mutation
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Dilated Cardiomyopathy (DCM)
BAG3 Mutation Associated Dilated Cardiomyopathy
Intervention:
GENETIC: AFTX-201
AFTX-201 is a gene therapy product consisting of th...